Fluorescein

A water-free cyclosporine 0.1% solution demonstrated superiority over vehicle in corneal fluorescein staining among adults with moderate to severe dry eye disease, according to a study conducted in China and published in JAMA Ophthalmology.

NEW ORLEANS — At the ARVO meeting, Andrew D. Pucker, OD, PhD, senior director of clinical and medical sciences at Lexitas Pharma Services, speaks about the Lexitas modified NEI grading scale to assess corneal fluorescein staining.

Healio spoke with Leslie O’Dell, OD, FAAO, medical director and director of clinical research at Medical Optometry America in Shrewsbury, about research needs and upcoming treatment options for patients with dry eye disease.

The evaluation of dry eye disease severity and treatment success could significantly be affected by early grading of corneal fluorescein staining, according to a study published in The Ocular Surface.

Recent data showed a greater incidence of ocular surface disease symptoms in patients receiving medical treatment for glaucoma, according to a study published in Clinical Ophthalmology.

Interim data from the PERSPECTIVE study showed statistically significant improvements in patients with severe keratitis who were treated with Ikervis, Santen announced in a press release.

VANCOUVER, British Columbia – Results from phase 2 and phase 3 trials showed that tivanisiran 1.125% significantly improved ocular discomfort/pain and conjunctival hyperemia in patients with dry eye and also confirmed its safety profile.